Tim Germann has been named vice president of sales of Metabolon, the firm announced this week. Germann previously led sales and marketing at US Genomics, and has held sales positions at Affymetrix, Molecular Devices, Stratagene, and Incyte Genomics.
Affymetrix has named James Gibson its new financial accounting officer, the company said in a recent US Securities and Exchange Commission filing.
Affymetrix said that its compensation committee has agreed to offer Gibson a base annual salary of $230,000 and granted him 7,500 restricted shares of the company’s common stock.
BioProcessors has named Jonathan Rennert president and CEO, the company said last week. Before joining BioProcessors, Rennert was vice president and general manager for analytical sciences at PerkinElmer. He previously held management and engineering positions at Carrier and at General Electric.
Fluidigm has hired Dominique Remy-Renou to be vice president of European sales and support and general manager of Fluidigm Europe.
Remy-Renou previously worked in the European organizations of Applied Biosystems.
Applied Biosystems on Jan. 1 raised its annual retainer for non-management board members from $60,000 to $70,000, the company said in a US Securities and Exchange Commission filing recently. The compensation package includes an annual retainer made of at least 50 percent stock and the remainder in cash, a stock options grant, and a restricted stock award.
Cepheid has amended and restated its employment agreement with CEO John Bishop, according to a US Securities and Exchange Commission filing this week. The amended agreement calls for Bishop to receive a base salary of $450,000 to be reviewed annually by the board of directors. In addition, it provides for an annual bonus plan with a target bonus of 40 percent of his salary.
Among other stipulations of the agreement, Cepheid also will rent a one-bedroom corporate apartment near the firm’s headquarters and reimburse Bishop for expenses incurred for weekly travel between Chicago and Sunnyvale, Calif.